Cargando…
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052253/ https://www.ncbi.nlm.nih.gov/pubmed/32123158 http://dx.doi.org/10.1038/s41408-020-0297-2 |
| _version_ | 1783502830928134144 |
|---|---|
| author | Gavriatopoulou, Maria Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Eleutherakis-Papaiakovou, Evangelos Papatheodorou, Athanasios Kanellias, Nikolaos Migkou, Magdalini Fotiou, Despina Dialoupi, Ioanna Roussou, Maria Kokkali, Nikoletta-Aikaterini Kastritis, Efstathios Dimopoulos, Meletios A. |
| author_facet | Gavriatopoulou, Maria Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Eleutherakis-Papaiakovou, Evangelos Papatheodorou, Athanasios Kanellias, Nikolaos Migkou, Magdalini Fotiou, Despina Dialoupi, Ioanna Roussou, Maria Kokkali, Nikoletta-Aikaterini Kastritis, Efstathios Dimopoulos, Meletios A. |
| author_sort | Gavriatopoulou, Maria |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7052253 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70522532020-03-05 Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma Gavriatopoulou, Maria Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Eleutherakis-Papaiakovou, Evangelos Papatheodorou, Athanasios Kanellias, Nikolaos Migkou, Magdalini Fotiou, Despina Dialoupi, Ioanna Roussou, Maria Kokkali, Nikoletta-Aikaterini Kastritis, Efstathios Dimopoulos, Meletios A. Blood Cancer J Correspondence Nature Publishing Group UK 2020-03-02 /pmc/articles/PMC7052253/ /pubmed/32123158 http://dx.doi.org/10.1038/s41408-020-0297-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Gavriatopoulou, Maria Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Eleutherakis-Papaiakovou, Evangelos Papatheodorou, Athanasios Kanellias, Nikolaos Migkou, Magdalini Fotiou, Despina Dialoupi, Ioanna Roussou, Maria Kokkali, Nikoletta-Aikaterini Kastritis, Efstathios Dimopoulos, Meletios A. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title_full | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title_fullStr | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title_full_unstemmed | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title_short | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| title_sort | consolidation with carfilzomib, lenalidomide, and dexamethasone (krd) following asct results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052253/ https://www.ncbi.nlm.nih.gov/pubmed/32123158 http://dx.doi.org/10.1038/s41408-020-0297-2 |
| work_keys_str_mv | AT gavriatopouloumaria consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT terposevangelos consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT ntanasisstathopoulosioannis consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT malandrakispanagiotis consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT eleutherakispapaiakovouevangelos consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT papatheodorouathanasios consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT kanelliasnikolaos consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT migkoumagdalini consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT fotioudespina consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT dialoupiioanna consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT roussoumaria consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT kokkalinikolettaaikaterini consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT kastritisefstathios consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma AT dimopoulosmeletiosa consolidationwithcarfilzomiblenalidomideanddexamethasonekrdfollowingasctresultsinhighratesofminimalresidualdiseasenegativityandimprovesbonemetabolismintheabsenceofbisphosphonatesamongnewlydiagnosedpatientswithmultiplemyeloma |